

RECEIVED  
CENTRAL FAX CENTER  
AUG 11 2005

Atty Docket No. 082368-001100US

PTO FAX NO.: 1-571-273-8300

ATTENTION: OIPE

## OFFICIAL COMMUNICATION

**ATTENTION: OIPE**

### CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of MASAI and TAMAI, Application No. 10/507,275, filed March 12, 2003 for CDC7-ASK KINASE COMPLEX, SUBSTRATES OF THE KINASE COMPLEX, SPECIFIC ANTIBODIES TO THE SUBSTRATES, AND SCREENING METHODS USING THE SAME TO SCREEN FOR COMPOUNDS COMPRISING CDC7-ASK KINASE INHIBITORY ABILITY are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Request for Corrected Filing Receipt (2 pp.); and
2. Marked-up copy of Filing Receipt (3 pp.).

Number of pages being transmitted, including this page: 6

Dated: August 11, 2005

  
Aaron Hokamra, Prosecution Paralegal

*PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300*

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, CA 94111-3834  
Telephone: 415-576-0200  
Fax: 415-576-0300  
2697

60561727 v1

RECEIVED  
CENTRAL FAX CENTER

AUG 11 2005

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on August 11, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

Aaron Hokamura

PATENTDocket No.: 082368-001100US  
Client Ref. No.: M3-A0201P-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MASAI and TAMAI

Application No.: 10/507,275

Filed: March 12, 2003

For: CDC7-ASK KINASE COMPLEX,  
SUBSTRATES OF THE KINASE  
COMPLEX, SPECIFIC ANTIBODIES  
TO THE SUBSTRATES, AND  
SCREENING METHODS USING THE  
SAME TO SCREEN FOR COMPOUNDS  
COMPRISING CDC7-ASK KINASE  
INHIBITORY ABILITY

Examiner:

Art Unit:

REQUEST FOR CORRECTED FILING  
RECEIPT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official Filing Receipt received from the Patent and Trademark Office for the above-identified application for which issuance of a corrected filing receipt is respectfully requested. The requested corrections are indicated in red on the attached Filing Receipt and listed below.

There is an error in the "Assignment For Published Patent Application" section of the Filing Receipt. Specifically, Assignees, "Japan Science and Technology Agency" and "Ginkgo Biomedical Research Institute Co., Ltd." are not listed. Applicant's respectfully request that the "Assignment For Published Patent Application" section be amended to read as follows:

MASAI and TAMAI  
Application No.: 10/507,275  
Page 2

PATENT

**Assignment for Published Patent Application**

Japan Science and Technology Agency, Kawaguchi-shi, Saitama, JAPAN

Medical and Biological Laboratories Co. Ltd., Nagoya-shi, Aichi, JAPAN


Ginkgo Biomedical Research Institute Co., Ltd., Minato-ku, Tokyo, JAPAN

Further, there is an error in the "Title" section of the Filing Receipt. The title was amended in a Preliminary Amendment filed with the application papers on September 9, 2004. Therefore, Applicants respectfully request that the "Title" section be corrected to read as follows:

**Title**

CDC7-ASK KINASE COMPLEX, SUBSTRATES OF THE KINASE  
COMPLEX, SPECIFIC ANTIBODIES TO THE SUBSTRATES, AND  
SCREENING METHODS USING THE SAME TO SCREEN FOR  
COMPOUNDS COMPRISING CDC7-ASK KINASE INHIBITORY  
ABILITY.

Applicants request that a corrected Filing Receipt be issued and all U.S. Patent and Trademark Office records be updated to reflect the requested corrections.

Respectfully submitted,  
  
Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
KLB:ath

60561541 v1

RECEIVED  
CENTRAL FAX CENTER

Page 1 of 3

AUG 11 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

KLB, SF

082368-001100US

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/507,275	06/08/2005	1645	1480	082368-001100US	8	14	8

CONFIRMATION NO. 2728

20350  
TOWNSEND AND TOWNSEND AND CREW, LLP  
TWO EMBARCADERO CENTER  
EIGHTH FLOOR  
SAN FRANCISCO, CA 94111-3834

## FILING RECEIPT



\*OC000000016571174\*

Date Mailed: 07/22/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Hisao Masai, Minato-ku, JAPAN;  
Katsuyuki Tamai, Ina-shi, JAPAN;

Japan Science and Technology Agency,  
Kawaguchi-shi, Saitama, Japan

## Assignment For Published Patent Application

Medical and Biological Laboratories Co. Ltd., Nagoya-shi, Aichi, JAPAN

Power of Attorney: The patent practitioners associated with Customer Number 20350.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/02918 03/12/2003

## Foreign Applications

JAPAN 2002-067702 03/12/2002

Ginkgo Biomedical Research Institute Co., Ltd.,  
Minato-ku, Tokyo, Japan

Projected Publication Date: 10/27/2005

Non-Publication Request: No

Early Publication Request: No

Title

Preliminary Class  
530

Cdc7-ask kinase complex, substrates of the kinase complex, antibody specific to the substrate, and method of screening compound capable of inhibiting cdc7-ask kinase using the same

Specific antibodies to the substrates, and screening methods using the same to screen for compounds comprising cdc7-ask kinase inhibitory ability.

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not result in a grant of "an international patent"** and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations

especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).